Working with GlaxoSmithKline and Merck on a new immunotherapy drug
MD Anderson’s research and collaboration with GlaxoSmithKline led to the development of GSK3174998, a new immunotherapy drug for patients with advanced solid tumors. This is now being tested in a Phase I clinical trial. The drug is administered as a single agent or in combination with another drug, Merck’s Keytruda. Both drugs are humanized monoclonal antibodies that plug into proteins on the surface of T cells, helping the immune system to destroy cancer cells.